Truvestments Capital’s Dianthus Therapeutics DNTH Stock Holding History

Truvestments Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.15K	Buy	+22	New	+$1.92K	﹤0.01%	1012

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Truvestments Capital's DNTH Position: Q2 2026 in Review

Truvestments Capital opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 22 shares worth $2.15K. The stake represents ﹤0.01% of the portfolio and ranks #1012 among its holdings.

268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Truvestments Capital held 22 shares of Dianthus Therapeutics worth $2.15K as of Q2 2026.
Dianthus Therapeutics was a new Truvestments Capital position in Q2 2026.
Dianthus Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #1012 holding.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.